Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana

Background : Buruli ulcer (BU) can lead to disfiguring ulcers and permanent disability. The 2030 World Health Organization (WHO) road map for Neglected Tropical Diseases (NTDs) calls for major scaling up in diagnosis and management to eliminate disability due to the disease. Current treatment for BU...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	NIHR open research 2022, Vol.2, p.59
Hauptverfasser:	Amoako, Yaw Ampem, Agbanyo, Abigail, Novignon, Jacob, Owusu, Lucy, Tuffour, Joseph, Asante-Poku, Adwoa, Hailemichael, Yohannes, Mosweu, Iris, Canter, Ruth, Opondo, Charles, Allen, Elizabeth, Pitt, Catherine, Yeboah-Manu, Dorothy, Walker, Stephen L., Marks, Michael, Phillips, Richard Odame
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!